Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

Abstract

A HDAC, kinase inhibitor hybrid, (<italic>Z</italic>)-N1-(3-((1<italic>H</italic>-pyrrol-2-yl)methylene)-2-oxoindolin-5-yl)-N8-hydroxyoctanediamide, <bold>6</bold>, showed impressive anticancer action in a number of biochemical and cell-based assays.